PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: [14C]PF00299804
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2010-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT01034748
- Locations
- πΊπΈ
Pfizer Investigational Site, Tacoma, Washington, United States
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Airway DiseaseCOPDLung DiseasesPulmonary Disease, Chronic ObstructiveRespiratory Tract Diseases
- Interventions
- Drug: placeboDrug: active comparator
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT01033487
- Locations
- π©πͺ
Pfizer Investigational Site, Berlin, Germany
Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction
Completed
- Conditions
- AsthmaPulmonary Disease, Chronic Obstructive
- Interventions
- Device: CRC-749Device: DiskusDevice: TwisthalerDevice: Miat Monohaler
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2010-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT01033669
- Locations
- π©πͺ
Pfizer Investigational Site, Berlin, Germany
The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis
Phase 2
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT01033396
- Locations
- π¨π¦
Pfizer Investigational Site, Kingston, Ontario, Canada
Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2011-12-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01032694
Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 123
- Registration Number
- NCT01032174
Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected
Phase 1
Completed
- Conditions
- Osteoarthritis PainChronic Low Back PainPain Due to Interstitial Cystitis
- Interventions
- Other: placeboBiological: tanezumab
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT01030640
- Locations
- πΊπΈ
Pfizer Investigational Site, Overland Park, Kansas, United States
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 145
- Registration Number
- NCT01029405
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT01028911
- Locations
- πΊπΈ
Pfizer Investigational Site, Wichita, Kansas, United States
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
Phase 3
Completed
- Conditions
- 13-valent Pneumococcal VaccineImmunizationSafetyAntibody Response
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 263
- Registration Number
- NCT01026038
- Locations
- π«π·
Pfizer Investigational Site, Vitry Sur Seine, France